Vaxcyte

Fact Sheet

PCVX

LISTED

NASDAQ

VAXCYTE

QUICK REFERENCE

Vaxcyte Inc.
Trading Symbol: PCVX

www.VAXCYTE.com

BUSINESS SUMMARY

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31 is a Phase 3-ready 31-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company's 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.

Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte's pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

GO-TO-MARKET STRATEGY

We are initially focusing our efforts on developing broadly protective vaccines for the following:

Pneumococcal disease is an infection caused by Streptococcus pneumoniae bacteria. It can result in invasive pneumococcal disease, including meningitis and bacteremia, and non-invasive pneumococcal disease, including pneumonia, otitis media and sinusitis. In the United States, approximately 320,000 people get pneumococcal pneumonia each year, resulting in approximately 150,000 hospitalizations and 5,000 deaths. Given these serious consequences, the public health community continues to affirm the need for broader-spectrum vaccines to prevent pneumococcal disease.

Group A Strep is a pervasive disease with no available preventive treatment that causes 700 million global cases of illness annually, including pharyngitis, or strep throat, and certain severe invasive infections such as sepsis, necrotizing fasciitis and toxic shock syndrome. The CDC has upgraded this disease as a threat because widespread use of some antibiotics has driven antimicrobial resistance, which has nearly tripled in the past decade.

Periodontitis is a widely prevalent disease without adequate therapies that affects an estimated 65 million US adults and causes measurable oral bone loss, tooth loss and chronic inflammation in more than half of Americans over the age of 40.

Shigella is a bacteria that causes dysentery and shigellosis, which has no available preventative treatment. Shigella affects an estimated 188 million people worldwide each year and results in approximately 164,000 deaths annually, mostly among children under five years of age in low- and middle-income areas. With the aim of reducing morbidity and mortality due to the disease, the World Health Organization lists Shigella vaccine development as a priority goal.

CONTACT INFORMATION

Headquarters
825 Industrial Road
San Carlos, CA 94070

Barwicki Investor Relations
Andrew Barwicki
516-662-9461 / andrew@barwicki.com

Recent Press Release *(Headline and Excerpts)*

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

-- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024

-- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program

-- VAX-24 Infant Phase 2 Study Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025

-- $1.9 Billion in Cash, Cash Equivalents and Investments as of June 30, 2024 --

Aug. 06, 2024 -- Vaxcyte, Inc. announced financial results for the second quarter ended June 30, 2024, and provided a business update.

Key Second Quarter and Recent Highlights

- VAX-24 Phase 2 Data in Adults Aged 65 and Older Published in Vaccine: In July 2024, the results from the VAX-24 Phase 2 study in adults aged 65 and older were published in the journal Vaccine. The study evaluated the safety, tolerability and immunogenicity of Vaxcyte's investigational 24-valent, carrier-sparing PCV compared to Prevnar 20® (PCV20), for the prevention of invasive pneumococcal disease (IPD) in healthy adults. The results showed VAX-24 demonstrated a safety and tolerability profile comparable to PCV20 across all ages and doses studied. The VAX-24 2.2mcg dose showed an overall improvement in immune responses compared to PCV20 relative to the results from the prior Phase 2 study in adults aged 50-64.
- National Institute of Allergy and Infectious Diseases (NIAID) Grant Awarded for Preclinical Chlamydia Vaccine Development Program: In July 2024, the NIAID awarded a five-year, $9.5 million grant to the University of North Carolina at Chapel Hill, Vaxcyte and the University of Chicago to develop a vaccine candidate for the prevention of Chlamydia. There is a significant need for a vaccine to protect against Chlamydia. It is the most common bacterial sexually transmitted infection worldwide, with nearly 130 million new cases per year. While it is treatable when detected early, it can cause permanent damage to the female reproductive system, potentially leading to complications such as infertility and ectopic pregnancy.
- Appointed Seasoned Industry Expert to its Board of Directors: In July 2024, Vaxcyte appointed John Furey to its Board of Directors. Mr. Furey is a seasoned biopharmaceutical executive with over 30 years of experience developing and implementing operational strategies and leading commercial and technical teams, including senior leadership roles in the U.S., Europe and Asia. He has extensive vaccine experience from his time at Baxter and Pfizer, including having served as the General Manager of Pfizer's vaccine business unit in China and a leadership role overseeing Pfizer Vaccines' global pricing and reimbursement. Earlier in his career, Mr. Furey held both commercial and operations positions at Wyeth Pharmaceuticals (prior to Pfizer's acquisition of Wyeth), including serving as Project Director of the Grange Castle Biopharmaceutical Campus where Prevnar is manufactured. He currently serves as Chief Executive Officer of Imvax, a clinical-stage biotechnology company developing novel immunotherapies for cancer. Mr. Furey earned an executive Master of Business Administration from Saint Joseph's University, a Bachelor of Science degree from Trinity College, Dublin, and a Diploma in Environmental Health from the Technological University, Dublin. Mr. Furey also serves on the Board of Directors of Adaptimmune and Sensorion.

Anticipated Key Milestones

Vaxcyte is advancing the clinical development of its PCV programs with several anticipated key upcoming milestones:

PCV Franchise Adult Indication:

- Announce topline safety, tolerability and immunogenicity data from VAX-31 adult Phase 1/2 study in September 2024.
- Following VAX-31 data, advance either VAX-24 or VAX-31 to an adult Phase 3 program.

If VAX-24:

- Following the initiation of Phase 3 pivotal, non-inferiority study in adults aged 50 and older, announce topline safety, tolerability and immunogenicity data in the second half of 2025.
- Initiate balance of expected Phase 3 studies in 2025 and 2026.

If VAX-31:

- Initiate full complement of expected Phase 3 studies in 2025 and 2026.

PCV Franchise Infant Indication:

VAX-24:

- Announce topline safety, tolerability and immunogenicity data from VAX-24 infant Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Vaxcyte Inc.
NASDAQ: PCVX

www.VAXCYTE.com

Barwicki Investor Relations * 30 Wall Street, 8 FL * New York, NY 10005

Deliver to: